清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Comparison of Pirfenidone and Nintedanib

医学 任天堂 吡非尼酮 内科学 特发性肺纤维化
作者
John S. Kim,Susan Murray,Eric Yow,Kevin J. Anstrom,Hyun Joo Kim,Kevin R. Flaherty,Fernando J. Martínez,Imre Noth
出处
期刊:Chest [Elsevier]
卷期号:165 (5): 1163-1173 被引量:7
标识
DOI:10.1016/j.chest.2023.11.035
摘要

Background

Antifibrotics are effective in slowing FVC decline in idiopathic pulmonary fibrosis (IPF). However, whether antifibrotic type is differentially associated with FVC decline remains inconclusive.

Research Question

Are there significant differences in 12-month FVC decline between pirfenidone and nintedanib?

Study Design and Methods

A post hoc analysis was performed using the CleanUP-IPF trial (No. NCT02759120). Participants who reported using pirfenidone or nintedanib on enrollment into the trial were in the primary analysis. Spirometry was scheduled at baseline and the 12- and 24-month study visits. Linear mixed-effects models with random intercept and slope were used to examine changes in FVC over time. Models were adjusted for age, sex, smoking history, coronary artery disease history, baseline FVC, and 12-month spline term. Survival and nonelective respiratory hospitalization by antifibrotic type were determined using Cox regression models with adjustment for age, sex, smoking history, coronary artery disease history, and baseline FVC and diffusing capacity for carbon monoxide.

Results

Out of the 513 participants with IPF randomized in the CleanUP-IPF trial, 407 reported using pirfenidone (n = 264, 65%) or nintedanib (n = 143, 35%). The pirfenidone group had more participants with a history of coronary artery disease than the nintedanib group (34.1% vs 20.3%, respectively). Patients treated with nintedanib had a higher 12-month visit FVC than patients treated with pirfenidone (mean difference, 106 mL; 95% CI, 34-178). This difference was attenuated at the 24-month study visit. There were no significant differences in overall survival and nonelective respiratory hospitalization between the pirfenidone- and nintedanib-treated groups.

Interpretation

Patients with IPF who used nintedanib had a slower 12-month FVC decline than pirfenidone in a post hoc analysis of a clinical trial.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小羊咩完成签到 ,获得积分10
2分钟前
Echan完成签到,获得积分10
3分钟前
Echan发布了新的文献求助10
3分钟前
3分钟前
风中凡霜发布了新的文献求助10
3分钟前
h7525yanghan完成签到 ,获得积分20
4分钟前
JJ完成签到 ,获得积分10
4分钟前
刘刘完成签到 ,获得积分10
5分钟前
5分钟前
快乐的睫毛完成签到 ,获得积分10
6分钟前
车访枫完成签到 ,获得积分10
7分钟前
老姚完成签到,获得积分10
7分钟前
肆肆完成签到,获得积分10
8分钟前
不配.应助明理问柳采纳,获得10
9分钟前
Lucas应助Echan采纳,获得10
9分钟前
实力不允许完成签到 ,获得积分10
10分钟前
谭凯文完成签到 ,获得积分10
11分钟前
丘比特应助科研通管家采纳,获得10
11分钟前
明理问柳完成签到,获得积分10
11分钟前
15分钟前
Echan发布了新的文献求助10
15分钟前
doreen完成签到 ,获得积分10
15分钟前
中央发布了新的文献求助10
16分钟前
zxq1996完成签到 ,获得积分10
16分钟前
16分钟前
Nemo发布了新的文献求助30
16分钟前
17分钟前
Malmever发布了新的文献求助10
17分钟前
科目三应助黙宇循光采纳,获得10
17分钟前
17分钟前
黙宇循光发布了新的文献求助10
17分钟前
Jj7完成签到,获得积分10
17分钟前
lena完成签到,获得积分10
18分钟前
田様应助黙宇循光采纳,获得10
19分钟前
19分钟前
爆米花应助科研通管家采纳,获得10
19分钟前
黙宇循光发布了新的文献求助10
19分钟前
19分钟前
希勤发布了新的文献求助10
19分钟前
林才发布了新的文献求助10
19分钟前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Le dégorgement réflexe des Acridiens 800
Defense against predation 800
XAFS for Everyone (2nd Edition) 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3133981
求助须知:如何正确求助?哪些是违规求助? 2784836
关于积分的说明 7768760
捐赠科研通 2440219
什么是DOI,文献DOI怎么找? 1297295
科研通“疑难数据库(出版商)”最低求助积分说明 624920
版权声明 600792